Abstract
Plasmodium vivax is the most world-widely distributed and the most prevalent species in America. Vaccine development for P. vivax is considered a priority in the global program for the eradication of malaria. In contrast to P. falciparum, currently, there are no human vaccine trials described against infection to P. vivax. We hypothesize that an effective vaccine formulation should be com…